A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Refractory Polymyositis and Dermatomyositis

OBJECTIVE: To investigate in a pilot study the safety and efficacy of infliximab in patients with refractory dermatomyositis (DM) and polymyositis (PM). METHODS: Participants received infusions of either placebo or infliximab 5 mg/kg at 0, 2, 6 and 14 weeks in blinded manner. The primary outcome was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Semin Arthritis Rheum
Main Authors: Schiffenbauer, Adam, Sawhney, Megha, Castro, Christine, Pokrovnichka, Angelina, Joe, Galen, Shrader, Joseph, Cabalar, Imelda Victoria, Harris-Love, Michael O., Plotz, Paul H., Miller, Frederick W., Gourley, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6208161/
https://ncbi.nlm.nih.gov/pubmed/29174792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.semarthrit.2017.10.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados